Cubist Systematic Strategies, LLC Neurocrine Biosciences Inc Transaction History

Cubist Systematic Strategies, LLC

$14.3 Billion
Q2 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $4.02 Million - $4.43 Million	30,854 Added 110.81%	58,697 $8.1 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $8.99 Million - $11.3 Million	-84,781 Reduced 75.28%	27,843 $3.67 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $413,593 - $515,122	4,399 Added 4.06%	112,624 $12.7 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $2.31 Million - $2.71 Million	-25,833 Reduced 19.27%	108,225 $10.2 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $6.18 Million - $8.08 Million	-65,716 Reduced 32.9%	134,058 $13.6 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $4.71 Million - $5.61 Million	44,176 Added 28.39%	199,774 $23.9 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $9.94 Million - $11.6 Million	108,011 Added 226.98%	155,598 $16.5 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $9.94 Million - $11.6 Million	108,011 Added 226.98%	155,598 $16.5 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $855,744 - $1.13 Million	11,291 Added 31.11%	47,587 $4.64 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $1.56 Million - $2.04 Million	-21,546 Reduced 37.25%	36,296 $3.4 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $2.83 Million - $3.78 Million	35,567 Added 159.67%	57,842 $4.93 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $13,702 - $15,745	159 Added 0.72%	22,275 $2.14 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $311,305 - $356,001	-3,481 Reduced 13.6%	22,116 $2.15 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $998,910 - $1.36 Million	11,407 Added 80.39%	25,597 $2.49 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $3.18 Million - $3.97 Million	-36,645 Reduced 72.09%	14,190 $1.36 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $1.15 Million - $1.62 Million	11,961 Added 30.77%	50,835 $4.89 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $2.25 Million - $3.45 Million	26,461 Added 213.17%	38,874 $4.74 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $6.34 Million - $9.61 Million	-84,452 Reduced 87.19%	12,413 $1.07 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $6.78 Million - $9.26 Million	78,073 Added 415.46%	96,865 $10.4 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $1.46 Million - $1.77 Million	-17,394 Reduced 48.07%	18,792 $1.69 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $1.48 Million - $1.87 Million	20,506 Added 130.78%	36,186 $3.06 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $357,085 - $471,562	5,152 Added 48.94%	15,680 $1.38 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $2.72 Million - $4.94 Million	-39,745 Reduced 79.06%	10,528 $752,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $4.75 Million - $6.05 Million	48,073 Added 2185.14%	50,273 $6.18 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $165,660 - $233,178	2,200 New	2,200 $216,000
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $388,429 - $473,149	-5,119 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $198,006 - $262,486	3,383 Added 194.87%	5,119 $397,000
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $83,275 - $106,382	1,736	1,736 $106,000

Others Institutions Holding NBIX

# of Institutions

641

Shares Held

95.3M

Call Options Held

661K

Put Options Held

227K

Black Rock Inc. New York, NY

14.2M
Shares

$1.63 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$1.16 Billion
0.03% of portfolio
State Street Corp Boston, MA

4.61M
Shares

$530 Million
0.03% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.47M
Shares

$284 Million
0.6% of portfolio
Jpmorgan Chase & CO New York, NY

2.36M
Shares

$272 Million
0.03% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account